207 related articles for article (PubMed ID: 19828631)
1. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
Böhm C; Hayer S; Kilian A; Zaiss MM; Finger S; Hess A; Engelke K; Kollias G; Krönke G; Zwerina J; Schett G; David JP
J Immunol; 2009 Nov; 183(9):5938-47. PubMed ID: 19828631
[TBL] [Abstract][Full Text] [Related]
2. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
4. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S; Ma JY; Mangadu R; Jiang Y; Zhao JJ; Almirez R; Kerr I; Stebbins EG; O'Young G; Kapoun AM; Luedtke G; Chakravarty S; Dugar S; Genant HK; Protter AA
J Pharmacol Exp Ther; 2006 Jul; 318(1):132-41. PubMed ID: 16597712
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells protect from local and systemic bone destruction in arthritis.
Zaiss MM; Frey B; Hess A; Zwerina J; Luther J; Nimmerjahn F; Engelke K; Kollias G; Hünig T; Schett G; David JP
J Immunol; 2010 Jun; 184(12):7238-46. PubMed ID: 20483756
[TBL] [Abstract][Full Text] [Related]
6. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis.
Korb A; Tohidast-Akrad M; Cetin E; Axmann R; Smolen J; Schett G
Arthritis Rheum; 2006 Sep; 54(9):2745-56. PubMed ID: 16947383
[TBL] [Abstract][Full Text] [Related]
7. Reduced p38 mitogen-activated protein kinase in donor grafts accelerates acute intestinal graft-versus-host disease in mice.
Ohta M; Tateishi K; Kanai F; Ueha S; Guleng B; Washida M; Tanaka Y; Ijichi H; Ikenoue T; Sata M; Sudo T; Shiina S; Kawabe T; Matsushima K; Omata M
Eur J Immunol; 2005 Jul; 35(7):2210-21. PubMed ID: 15971269
[TBL] [Abstract][Full Text] [Related]
8. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation.
Perdiguero E; Ruiz-Bonilla V; Gresh L; Hui L; Ballestar E; Sousa-Victor P; Baeza-Raja B; Jardí M; Bosch-Comas A; Esteller M; Caelles C; Serrano AL; Wagner EF; Muñoz-Cánoves P
EMBO J; 2007 Mar; 26(5):1245-56. PubMed ID: 17304211
[TBL] [Abstract][Full Text] [Related]
12. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
[TBL] [Abstract][Full Text] [Related]
13. JNK1 is not essential for TNF-mediated joint disease.
Köller M; Hayer S; Redlich K; Ricci R; David JP; Steiner G; Smolen JS; Wagner EF; Schett G
Arthritis Res Ther; 2005; 7(1):R166-73. PubMed ID: 15642137
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 directly inhibits osteoclast formation.
Axmann R; Herman S; Zaiss M; Franz S; Polzer K; Zwerina J; Herrmann M; Smolen J; Schett G
Ann Rheum Dis; 2008 Nov; 67(11):1603-9. PubMed ID: 18203760
[TBL] [Abstract][Full Text] [Related]
15. A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.
Kirkwood KL; Li F; Rogers JE; Otremba J; Coatney DD; Kreider JM; D'Silva NJ; Chakravarty S; Dugar S; Higgins LS; Protter AA; Medicherla S
J Pharmacol Exp Ther; 2007 Jan; 320(1):56-63. PubMed ID: 17041006
[TBL] [Abstract][Full Text] [Related]
16. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.
Lee MS; Kim HS; Yeon JT; Choi SW; Chun CH; Kwak HB; Oh J
J Immunol; 2009 Sep; 183(5):3390-9. PubMed ID: 19641137
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
18. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis.
Hayer S; Redlich K; Korb A; Hermann S; Smolen J; Schett G
Arthritis Rheum; 2007 Jan; 56(1):79-88. PubMed ID: 17195210
[TBL] [Abstract][Full Text] [Related]
19. p38 MAP kinase inhibitors: many are made, but few are chosen.
Dominguez C; Powers DA; Tamayo N
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice.
Schurigt U; Hummel KM; Petrow PK; Gajda M; Stöckigt R; Middel P; Zwerina J; Janik T; Bernhardt R; Schüler S; Scharnweber D; Beckmann F; Saftig P; Kollias G; Schett G; Wiederanders B; Bräuer R
Arthritis Rheum; 2008 Feb; 58(2):422-34. PubMed ID: 18240253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
